We are a global family

We are pulmonary hypertension professionals united in our vision for a world without pulmonary vascular disease. We believe we can achieve this together, and we won’t stop until we do.

PVRI 2025 Rio: Embracing Heterogeneity

2 weeks to go until PVRI 2025 Rio: Embracing Heterogeneity! Taking place 29 January - 1 February 2025, register your place today. See you in Rio!

Career Catalyst Luncheon at PVRI 2025

New for our Annual Congress, we will be hosting a Career Catalyst Luncheon to support early career professionals and trainees to connect with globally renowned senior and mid-career PH professionals in a welcoming and informal setting.

Find out more

Join our family

Whether you’re a pulmonary hypertension specialist, a pharmaceutical or industry colleague, a regulator, a patient, or a caregiver, joining our growing global family means you share our vision to reduce the global burden of pulmonary vascular disease.

Become a member

Paul Hassoun and Martin Wilkins, PVRI Drinks Reception, Vienna 2024

Registration is open for DDDS 2025

We are excited to announce that registration is open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam. See our event page for more details and register your place!

Featured events

PVRI 2025 Rio: Embracing Heterogeneity

29 January 2025

The PVRI 2025 Annual Congress will be hosted in the vibrant city of Rio de Janeiro at the Windsor Convention & Expo Centre. Esteemed experts, healthcare professionals, and researchers from around the globe will converge in this iconic city to share groundbreaking insights, foster collaborations, and advance our collective mission towards conquering PVD. Register your place!

SARS-CoV2: From speculation to mechanism in pulmonary arterial hypertension

19 February 2025

Webinar presentations: SARS-CoV-2 spike protein impairs endothelial function via downregulation of ACE2; Antifibrotic therapies for pulmonary fibrosis-induced pulmonary hypertension caused by SARS-CoV-2; Perfusion imaging of the pulmonary vasculature after SARS-CoV-2 infection; Endothelial biomarkers of disease severity in SARS-CoV-2 infected patients

A PH Group III webinar

20 February 2025

A PH Group III webinar. Presentations: Is there evidence for different phenotypes of PH in ILD? Treatment of pulmonary vascular disease in ILD: as early as possible or only in severe PH?

Adverse events in COPD and Healthy at high altitude

15 April 2025

Part of the Hypoxia in pulmonary vascular research – altitude and beyond webinar series

Featured learning and research

Session 4 of Young Investigator Symposium

Webinar presentations: Cardiopulmonary networks: bridging infection and microbiome in pulmonary vascular disease; Inflammasome activation in pulmonary arterial hypertension; Role of oxidative signals in endothelial phenotypes in PH; Spironolactone: an old drug with new tricks; HIPPO/MST signaling via BUB3 and FOXO drives pulmonary vascular cell growth and survival

Comparing Patency of Pulmonary Stent Implantation and Balloon Angioplasty in Pulmonary Vein Stenosis: A Systematic Review and Meta-Analysis

Pulmonary vein stenosis (PVS) is an insidious diagnosis associated with morbidity and mortality. Pharmacologic therapy may suffice initially, but advanced stages demand mechanical intervention. Pulmonary stent implantation (PSI) and pulmonary balloon angioplasty (PBA) are common strategies, both carrying restenosis risks.

Disparities in Clinical Outcomes Observed Within Electronic Health Record Data From a Statewide Cohort of Pulmonary Arterial Hypertension Patients

Health disparities in patients with pulmonary arterial hypertension (PAH) have not been extensively reported in the United States. The aim of this project was to characterize the extent of demographic and socioeconomic disparities in clinical outcomes within a large, diverse PAH patient population.

Elective Thoracic Surgical Resections for Pulmonary Arteriovenous Malformations - A 16 Year Single-Center Experience

Pulmonary arteriovenous malformations (PAVMs) cause cerebral abscess and ischemic stroke due to paradoxical emboli, risks that are increasingly recognized. We report the evolving placement of thoracic surgery in multi-disciplinary team management of PAVMs that were sporadic or associated with hereditary hemorrhagic telangiectasia.

News

Hot topics from PVRI GoDeep at PVRI 2025

Hot topics from PVRI GoDeep, led by Werner Seeger, is a session in the PVRI 2025 programme and will take place on Saturday, 1 February 2025. Presentations include: Overview of the GoDeep meta-registry; Risk scores beyond group 1 PH – baseline and follow-up; Survival outcomes and impact of targeted PAH therapy in PoPH; PAH-targeted therapies in group 3 PH – PDE5 inhibitor therapy associated with improved survival; Male survival disadvantage in PH: independent of etiology, age, disease severity, comorbidities and treatment, but race-dependent

Drug Discovery and Development Symposium 2025 - Registration open

We are excited to announce that registration is open for the PVRI Drug Discovery and Development Symposium 2025! #DDDS2025 will be taking place 16-17 June 2025 in Amsterdam and promises to be an excellent opportunity for regulatory, industry, and academic bodies to meet and discuss the latest drug developments in PH.

Unlocking insights - the potential of the PH GPS

On 27 September 2024, phase 1 of the Pulmonary Hypertension Global Patient Survey (PH GPS) closed. The survey was first launched in October 2023 to help clinicians better understand the impacts of PH on patients.

World Heart Day, USE ❤️ FOR ACTION

This World Heart Day, PVRI supports the WHF campaign calling for increased awareness, better healthcare policies and more funding for heart health research.